Железодефицит в кардиологии – новая терапевтическая мишень?

1. Boyd CM, Leff B, Wolff JL et al. Informing clinical practice guideline development and implementation: prevalence of coexisting conditions among adults with coronary heart disease. J Am Geriatr Soc 2011; 59 (5): 797–805.
2. Jankowska EA, Rozentryt P, Witkowska A et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31 (15): 1872–80.
3. Sabatine MS, Morrow DA, Giugliano RP et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111 (16): 2042–9.
4. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110 (2): 149–54.
5. O'Meara E, Clayton T, McEntegart MB et al. Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006; 113 (7): 986–94.
6. Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int 2003; 64 (Suppl. 87): S32–9.
7. Vlagopoulos PT, Tighiouart H, Weiner DE et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16 (11): 3403–10.
8. Sullivan JL: Iron and the sex difference in heart disease risk. Lancet 1981: 1293–4.
9. Weissert S, Flint J, Aggarwal S et al. Iron Deficiency as the Most Ominous Substrate for Anemia in Patients Undergoing Coronary Artery Bypass Surgery. Circulation 2011; 124: A17396.
10. Cook JD, Lipschitz DA, Miles LE et al. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 1974; 27: 681–7.
11. Burt MJ, Halliday JW, Powell LW. Iron and coronary heart disease. BMJ 1993; 307: 575–6.
12. Cooper CE: Nitric oxide and iron proteins. Biochim Biophys Acta 1999; 1411: 290–309.
13. Ponka P. Cellular iron metabolism. Kidney Int 1999; 55 (69): S2–S11.
14. Cairo G, Bernuzzi F, Recalcati S. Apreciousmetal: iron, an essential nutrient for all cells. Genes and Nutrition 2006; 1: 25–40.
15. Anderson GJ, Vulpe CD. Mammalian iron transport. Cellular and Molecular Life Sciences 2009; 66 (20): 3241–61.
16. Dallman PR. Iron deficiency: does it matter? J Intern Med 1989; 226: 367–72.
17. Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001; 131: 676S–88S.
18. Anker SD, Colet JC, Filippatos G et al. FAIR-HF committees and investigators.. Rationale and design of Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009; 11: 1084–91.
19. Weiss G, Goodnough LT. Anemia of Chronic Disease. New Eng J Med 2005; 352 (10): 1011–23.
20. Mastromarino V, Volpe M, Musumeci MB et al. Erythropoietin and the heart: facts and perspectives. Clin Sci 2011; 120 (2): 51–63.
21. Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 2003; 60 (1): S93–102.
22. Silverberg DS, Wexler D, Iaina A, Schwartz D. Correction of iron deficiency in the cardiorenal syndrome. Int J Nephrol 2011; 2011: 365301.
23. http://www.who.int/vmnis/indicators/serum_ferritin_ru.pdf
24. Kansagara D, Dyer E, Englander H et al. Treatment of Anemia in Patients with Heart Disease: A Systematic Review [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011 Oct. http://www.ncbi.nlm.nih.gov/books/NBK83423/pdf/TOC.pdf
25. Anker SD, Comin CJ, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New Eng J Med 2009; 361 (25): 2436–48.
26. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NTpro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Col Cardiol 2007; 50 (17): 1657–65.
27. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Col Cardiol 2008; 51 (2): 103–12.
28. Van Wyck DB, Roppolo M, Martinez CO et al. for the United States Iron Sucrose (Venofer) Clinical Trials Group: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: 2846–56.
29. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 897–906.
30. Palazzuoli A, Silverberg DS, Iovine F et al. Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154 (4): 645e9–645e15.
31. Krum H, Jelinek MV, Stewart S et al. National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust 2011; 194 (8): 405–9.

Ф.Ю.Копылов 

Кафедра профилактической и неотложной кардиологии ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ